Cyclerion Therapeutics’ zagociguat was granted FDA orphan designation as a treatment of mitochondrial disease, according to a post to the agency’s website. Reference Link
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CYCN: